Drug intelligence / Profile preview

SLC-037

Development stage: Preclinical
Lead developer: Savior Lifetec
Modality: Small Molecules
Administration: Parenteral

Overview

**SLC-037** is a preclinical small-molecule combination-antibiotic program from Savior Lifetec for carbapenem-resistant bacterial infections. The program is described as part of the company's next-generation carbapenem-antibiotic portfolio and is intended to incorporate novel beta-lactamase inhibition to protect antibacterial activity against beta-lactamase-mediated resistance.

Targets

β-lactamase

Beyond the preview

Go deeper on SLC-037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC-037.

Explore the full profile